RecruitingPHASE1, PHASE2NCT05776069
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
Studying Von Willebrand disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vega Therapeutics, Inc
- Intervention
- VGA039(drug)
- Enrollment
- 116 target
- Eligibility
- 12-60 years · All sexes
- Timeline
- 2023 – 2029
Study locations (25)
- Orthopedic Institute for Children (UCLA), Los Angeles, California, United States
- UC Davis Medical Center, Sacramento, California, United States
- University of Colorado School of Medicine, Aurora, Colorado, United States
- Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Atlanta, Georgia, United States
- Science 37, Inc., Morrisville, North Carolina, United States
- Hemophilia Center of Western PA, Pittsburgh, Pennsylvania, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- University of Texas Southwestern, Dallas, Texas, United States
- Washington Center for Bleeding Disorders, Seattle, Washington, United States
- Versiti Comprehensive Center for Bleeding Disorders, Milwaukee, Wisconsin, United States
- Royal Brisbane & Women's Hospital, Queensland Haemophilia Centre, Herston, Queenland, Australia
- Medical University of Vienna, Vienna, Vienna, Austria
- Centro de Hemoterapia e Hematologia do Rio de Janeiro HEMORIO, Rio de Janeiro, Rio de Janeiro, Brazil
- Hemocentro Unicamp, Campinas, São Paulo, Brazil
- Hospital das Clinicas - USP Endereco, São Paulo, São Paulo, Brazil
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05776069 on ClinicalTrials.govOther trials for Von Willebrand disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07404644An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT07115004Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)Vega Therapeutics, Inc
- RECRUITINGPHASE3NCT07129343A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT06998524A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseHoffmann-La Roche
- RECRUITINGNCT06883240An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care TreatmentHoffmann-La Roche
- RECRUITINGPHASE3NCT05582993A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT06205095A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWDUnity Health Toronto
- ACTIVE NOT RECRUITINGNCT03853486ATHN 9: Severe VWD Natural History StudyAmerican Thrombosis and Hemostasis Network